Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SPRB Spruce Biosciences, Inc.

Closed 12-23 16:00:00 EST

0.3775

-0.0225

-5.62%

盘后0.3780

+0.0005+0.13%

19:52 EST

High0.3948	Low0.3650	Vol770.58K
Open0.3833	D1 Closing0.4000	Amplitude7.45%
Mkt Cap15.59M	Tradable Cap8.21M	Total Shares41.30M
T/O289.20K	T/O Rate3.54%	Tradable Shares21.75M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SPRB","market":"US","secType":"STK","nameCN":"Spruce Biosciences, Inc.","latestPrice":0.3775,"timestamp":1734987600000,"preClose":0.4,"halted":0,"volume":770583,"hourTrading":{"tag":"盘后","latestPrice":0.378,"preClose":0.3775,"latestTime":"19:52 EST","volume":310,"amount":118.1293,"timestamp":1735001564827},"delay":0,"floatShares":21749234,"shares":41302599,"eps":-0.959594,"marketStatus":"Closed","change":-0.0225,"latestTime":"12-23 16:00:00 EST","open":0.3833,"high":0.3948,"low":0.365,"amount":289203.37540512,"amplitude":0.0745,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.959594,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1735030800000},"marketStatusCode":5,"adr":0,"listingDate":1602216000000,"exchange":"NASDAQ","adjPreClose":0.4,"preHourTrading":{"tag":"盘前","latestPrice":0.3734,"preClose":0.4,"latestTime":"09:27 EST","volume":2292,"amount":888.5938228800001,"timestamp":1734964072964},"postHourTrading":{"tag":"盘后","latestPrice":0.378,"preClose":0.3775,"latestTime":"19:52 EST","volume":310,"amount":118.1293,"timestamp":1735001564827},"volumeRatio":1.750719,"impliedVol":2.1296,"impliedVolPercentile":0.866},"requestUrl":"/m/hq/s/SPRB","defaultTab":"news","newsList":[{"id":"2491302917","title":"Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2491302917","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491302917?lang=en_us&edition=fundamental","pubTime":"2024-12-14 01:00","pubTimestamp":1734109212,"startTime":"0","endTime":"0","summary":"Spruce Biosciences, Inc.  could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 . This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.Therefore, the Zacks rating upgrade for Spruce Biosciences basically reflects positivity about its earnings outlook that could translate into buying pressure a","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/w.ILboV799eZj6zbyZJ3SQ--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5ecaf2a9bf082a5f3a554e6526b34be0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/w.ILboV799eZj6zbyZJ3SQ--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5ecaf2a9bf082a5f3a554e6526b34be0"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spruce-biosciences-sprb-upgraded-buy-170012470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRB"],"gpt_icon":0},{"id":"2490860970","title":"Oppenheimer Downgrades Spruce Biosciences to Perform From Outperform, Removes $3 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2490860970","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490860970?lang=en_us&edition=fundamental","pubTime":"2024-12-12 00:59","pubTimestamp":1733936352,"startTime":"0","endTime":"0","summary":"Price: 0.40, Change: -0.13, Percent Change: -24.77","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPRB","OPY"],"gpt_icon":0},{"id":"2490291864","title":"Spruce Biosciences Price Target Cut to $1.50/Share From $2.00 by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2490291864","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490291864?lang=en_us&edition=fundamental","pubTime":"2024-12-12 00:06","pubTimestamp":1733933160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPRB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2024 11:06 ET (16:06 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB"],"gpt_icon":0},{"id":"2490687798","title":"JMP Securities Downgrades Spruce Biosciences to Market Perform From Market Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2490687798","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490687798?lang=en_us&edition=fundamental","pubTime":"2024-12-11 22:42","pubTimestamp":1733928122,"startTime":"0","endTime":"0","summary":"Spruce Biosciences (SPRB) has an average rating of Hold and mean price target of $1.01, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPRB","JMP"],"gpt_icon":0},{"id":"2490585475","title":"Spruce Biosciences : Oppenheimer Cuts to Perform From Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2490585475","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490585475?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:28","pubTimestamp":1733923706,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nAZN2T3EBA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRB","BK4139"],"gpt_icon":0},{"id":"2490869850","title":"Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2490869850","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490869850?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:21","pubTimestamp":1733923313,"startTime":"0","endTime":"0","summary":"On Tuesday, Spruce Biosciences, Inc. revealed topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH.Congenital adrenal hyperplasia  isa genetic disease that affects the adrenal glands and prevents the production of hormones like cortisol, aldosterone, and androgens.Also Read: Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disorder. “In the interim, the CAHmelia-204 and CAHptain-205 clinical trials will be discontinued, and we will be winding down Spruce’s investment in tildacerfont for the treatment of CAH as we conserve financial resources and look to maximize shareholder value,” said Javier Szwarcberg, CEO of Spruce.CAHmelia-204 was a Phase 2b trial that evaluated the safety and efficacy of tildacerfont in reducing supraphysiologic GC usage in 100 adults with classic CAH on a mean glucocorticoid  dose of 35mg/day of hydrocortisone equival","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ASC6G8CrymBSlRazc.4lsA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/211c4676e2046f2b4f7c5c7afad23050","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ASC6G8CrymBSlRazc.4lsA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/211c4676e2046f2b4f7c5c7afad23050"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/penny-stock-spruce-biosciences-winds-132153597.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4175","SPRB","LU0162691827.USD","BK4139","LU0310799852.SGD","LU0211327993.USD","BK4585","CAH","LU0052756011.USD","LU0072461881.USD","LU1267930813.SGD","BK4121","LU1571399168.USD","SG9999001440.SGD","LU1267930490.SGD","LU0211328371.USD","LU0128525689.USD","LU0889566641.SGD","LU0006061336.USD","GENE","LU1880398471.USD","LU0310800965.SGD","LU1267930227.SGD","LU0792757196.USD","LU1880398554.USD","BK4588"],"gpt_icon":0},{"id":"2490856398","title":"RBC Cuts Price Target on Spruce Biosciences to $1.50 From $2, Keeps Sector Perform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2490856398","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490856398?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:25","pubTimestamp":1733919918,"startTime":"0","endTime":"0","summary":"RBC Cuts Price Target on Spruce Biosciences to $1.50 From $2, Keeps Sector Perform, Speculative Risk","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPRB"],"gpt_icon":0},{"id":"2490837421","title":"Spruce Biosciences Cut to Perform From Outperform by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2490837421","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490837421?lang=en_us&edition=fundamental","pubTime":"2024-12-11 19:13","pubTimestamp":1733915580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPRB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2024 06:13 ET (11:13 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","OPY"],"gpt_icon":0},{"id":"2490312988","title":"Spruce Biosciences Downgraded to Hold Amid Unmet Clinical Trial Endpoints and Strategic Reevaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2490312988","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490312988?lang=en_us&edition=fundamental","pubTime":"2024-12-11 18:16","pubTimestamp":1733912212,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Leland Gershell has maintained their neutral stance on SPRB stock, giving a Hold rating yesterday. Leland Gershell’s rating is ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/spruce-biosciences-downgraded-to-hold-amid-unmet-clinical-trial-endpoints-and-strategic-reevaluation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/spruce-biosciences-downgraded-to-hold-amid-unmet-clinical-trial-endpoints-and-strategic-reevaluation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRB"],"gpt_icon":0},{"id":"2490004003","title":"JMP Securities downgrades Spruce Biosciences (SPRB) to a Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2490004003","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490004003?lang=en_us&edition=fundamental","pubTime":"2024-12-11 10:27","pubTimestamp":1733884048,"startTime":"0","endTime":"0","summary":"Spruce Biosciences (SPRB – Research Report) received a Hold rating and price target from JMP Securities analyst Jonathan Wolleben yesterday. The co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jmp-securities-downgrades-spruce-biosciences-sprb-to-a-hold?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jmp-securities-downgrades-spruce-biosciences-sprb-to-a-hold?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRB","JMP"],"gpt_icon":0},{"id":"2490027403","title":"BRIEF-Spruce Biosciences Announces Topline Results From Cahmelia-204 In Adult CAH And Cahptain-205 In Adult And Pediatric CAH","url":"https://stock-news.laohu8.com/highlight/detail?id=2490027403","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490027403?lang=en_us&edition=fundamental","pubTime":"2024-12-11 06:33","pubTimestamp":1733870036,"startTime":"0","endTime":"0","summary":"Dec 10  - Spruce Biosciences Inc   :   * SPRUCE BIOSCIENCES ANNOUNCES TOPLINE RESULTS FROM CAHMELIA-204 IN ADULT CAH AND CAHPTAIN-205 IN ADULT AND PEDIATRIC CAH   * SPRUCE BIOSCIENCES INC - CAHMELIA-204 STUDY DID NOT ACHIEVE PRIMARY ENDPOINT   * SPRUCE BIOSCIENCES INC - EVALUATING STRATEGIC OPPORTUNITIES AND COST-REDUCTION ACTIVITIES   * SPRUCE BIOSCIENCES INC - TO DISCONTINUE CAHMELIA-204 AND CAHPTAIN-205 TRIALS   * SPRUCE BIOSCIENCES INC: WILL BE WINDING DOWN SPRUCE'S INVESTMENT IN TILDACERFONT FOR TREATMENT OF CAHSource text:   Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAH","LU0162691827.USD","LU0052756011.USD","LU0792757196.USD","BK4139","SG9999001440.SGD","LU0211328371.USD","LU1880398554.USD","BK4175","LU0310799852.SGD","LU0072461881.USD","LU1571399168.USD","SPRB","LU0128525689.USD","LU0211327993.USD","LU1267930227.SGD","LU1267930490.SGD","LU0310800965.SGD","LU1880398471.USD","BK4588","LU0006061336.USD","LU1267930813.SGD","BK4585","LU0889566641.SGD"],"gpt_icon":0},{"id":"2490980027","title":"BUZZ-Spruce Biosciences drops after cutting investment for genetic disorder drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2490980027","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490980027?lang=en_us&edition=fundamental","pubTime":"2024-12-11 06:26","pubTimestamp":1733869596,"startTime":"0","endTime":"0","summary":"BUZZ-Spruce Biosciences drops after cutting investment for genetic disorder drug** Shares of drug developer Spruce Biosciences SPRB.O fall 18.25% to 43 cents in after-market trading** Co says it will be winding down investment in its experimental drug, tildacerfont, which was being developed as a treatment of congenital adrenal hyperplasia ** Co will also discontinue two studies for the drug** The drug failed to meet the main goal of reducing the usage of a steroid hormone known as glucocorticoid in a mid-stage trial conducted among adults with the disease** Results from another study of tildacerfont in adult and pediatric CAH patients suggest higher doses and twice-daily dosing may be needed ** CAH is a rare genetic condition that affects the body's ability to create and regulate key hormones** Adds evaluation of strategic opportunities and cost-reduction activities underway** Up to last close, stock down ~82% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nL4N3NB1TI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"gpt_icon":0},{"id":"2490026070","title":"Spruce Biosciences to wind down investment for genetic disorder drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2490026070","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490026070?lang=en_us&edition=fundamental","pubTime":"2024-12-11 05:11","pubTimestamp":1733865080,"startTime":"0","endTime":"0","summary":"Spruce Biosciences to wind down investment for genetic disorder drugDec 10  - Spruce Biosciences SPRB.O said on Tuesday it will wind down investments for its genetic disorder drug after it failed to meet the main goal in a mid-stage study.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nL4N3NB1OF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"gpt_icon":0},{"id":"2490002952","title":"Spruce Biosciences Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2490002952","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490002952?lang=en_us&edition=fundamental","pubTime":"2024-12-11 05:05","pubTimestamp":1733864722,"startTime":"0","endTime":"0","summary":"16:00 EST Spruce Biosciences (SPRB) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving b...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spruce-biosciences-inc-trading-halted-news-pending-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spruce-biosciences-inc-trading-halted-news-pending-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRB","BK4139"],"gpt_icon":0},{"id":"2490029507","title":"Spruce Biosciences CAHmelia-204 study did not achieve primary efficacy endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2490029507","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490029507?lang=en_us&edition=fundamental","pubTime":"2024-12-11 05:05","pubTimestamp":1733864709,"startTime":"0","endTime":"0","summary":"Spruce Biosciences (SPRB) “announced topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildace...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spruce-biosciences-cahmelia-204-study-did-not-achieve-primary-efficacy-endpoint?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spruce-biosciences-cahmelia-204-study-did-not-achieve-primary-efficacy-endpoint?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SPRB"],"gpt_icon":0},{"id":"2490802615","title":"Spruce Biosciences Inc: Will Be Winding Down Spruce's Investment in Tildacerfont for Treatment of Cah","url":"https://stock-news.laohu8.com/highlight/detail?id=2490802615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490802615?lang=en_us&edition=fundamental","pubTime":"2024-12-11 05:01","pubTimestamp":1733864460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA54LFM8:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRB","BK4139"],"gpt_icon":0},{"id":"2490026667","title":"Spruce Biosciences Inc - Evaluating Strategic Opportunities and Cost-Reduction Activities","url":"https://stock-news.laohu8.com/highlight/detail?id=2490026667","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490026667?lang=en_us&edition=fundamental","pubTime":"2024-12-11 05:01","pubTimestamp":1733864460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA54LFM8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRB","BK4139"],"gpt_icon":0},{"id":"2490026661","title":"Spruce Biosciences Inc - to Discontinue Cahmelia-204 and Cahptain-205 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2490026661","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490026661?lang=en_us&edition=fundamental","pubTime":"2024-12-11 05:01","pubTimestamp":1733864460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA54LFM8:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRB","BK4139"],"gpt_icon":0},{"id":"2490026656","title":"Spruce Biosciences Announces Topline Results From Cahmelia-204 in Adult Cah and Cahptain-205 in Adult and Pediatric Cah","url":"https://stock-news.laohu8.com/highlight/detail?id=2490026656","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490026656?lang=en_us&edition=fundamental","pubTime":"2024-12-11 05:01","pubTimestamp":1733864460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA54LFM8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRB"],"gpt_icon":0},{"id":"2490021871","title":"Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH","url":"https://stock-news.laohu8.com/highlight/detail?id=2490021871","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490021871?lang=en_us&edition=fundamental","pubTime":"2024-12-11 05:01","pubTimestamp":1733864460,"startTime":"0","endTime":"0","summary":"CAHmelia-204 Study of 200mg Once-Daily  Tildacerfont in Adult Congenital Adrenal Hyperplasia  Did Not Achieve Primary Endpoint of Glucocorticoid  Reduction. Dose-Ranging Data from CAHptain-205 Study of Tildacerfont in Adult and Pediatric CAH Suggests Higher Doses and Twice-Daily  Dosing May Be Necessary for Efficacy in CAH. Evaluation of Strategic Opportunities and Cost-Reduction Activities Underway. SOUTH SAN FRANCISCO, Calif., December 10, 2024----Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological and endocrine disorders with significant unmet medical need, today announced topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH.CAHmelia-204 was a Phase 2b, randomized, double-blind, placebo-controlled clinical trial that evaluated the safety and efficacy of tildacerfont in reducing supraphysiologic GC usage in ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fraXl1V1Dnw6l9cg3qbbiQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/5d3044f78a8a4d55e395bebe3e0b750a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fraXl1V1Dnw6l9cg3qbbiQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/5d3044f78a8a4d55e395bebe3e0b750a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spruce-biosciences-announces-topline-results-210100696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAH","LU0162691827.USD","LU0052756011.USD","LU0792757196.USD","CRF","BK4139","SG9999001440.SGD","LU0211328371.USD","LU1880398554.USD","BK4175","LU0310799852.SGD","BK4563","LU0072461881.USD","LU1571399168.USD","SPRB","QD","LU0128525689.USD","BK4166","LU0211327993.USD","LU1267930227.SGD","LU1267930490.SGD","LU0310800965.SGD","LU1880398471.USD","BK4503","BK4588","LU0006061336.USD","LU1267930813.SGD","BK4585","LU0889566641.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sprucebiosciences.com","stockEarnings":[{"period":"1week","weight":0.0438},{"period":"1month","weight":-0.1837},{"period":"3month","weight":-0.0909},{"period":"6month","weight":-0.2195},{"period":"1year","weight":-0.8049},{"period":"ytd","weight":-0.8635}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.33989},{"month":2,"riseRate":0.5,"avgChangeRate":0.009378},{"month":3,"riseRate":0,"avgChangeRate":-0.297383},{"month":4,"riseRate":0,"avgChangeRate":-0.078867},{"month":5,"riseRate":0.5,"avgChangeRate":-0.003763},{"month":6,"riseRate":0.25,"avgChangeRate":-0.126985},{"month":7,"riseRate":0.5,"avgChangeRate":-0.017508},{"month":8,"riseRate":0.25,"avgChangeRate":-0.021147},{"month":9,"riseRate":0.5,"avgChangeRate":-0.141116},{"month":10,"riseRate":0.25,"avgChangeRate":-0.193698},{"month":11,"riseRate":0.6,"avgChangeRate":0.019777},{"month":12,"riseRate":0.4,"avgChangeRate":0.279898}],"exchange":"NASDAQ","name":"Spruce Biosciences, Inc.","nameEN":"Spruce Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Spruce Biosciences, Inc.(SPRB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Spruce Biosciences, Inc.,SPRB,Spruce Biosciences, Inc.股票,Spruce Biosciences, Inc.股票老虎,Spruce Biosciences, Inc.股票老虎国际,Spruce Biosciences, Inc.行情,Spruce Biosciences, Inc.股票行情,Spruce Biosciences, Inc.股价,Spruce Biosciences, Inc.股市,Spruce Biosciences, Inc.股票价格,Spruce Biosciences, Inc.股票交易,Spruce Biosciences, Inc.股票购买,Spruce Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Spruce Biosciences, Inc.(SPRB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction